Estimates Revisions DiaMedica Therapeutics Inc.
Stocks
DMAC
CA25253X2077
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 6.450 USD | +1.57% |
|
-4.30% | -18.97% |
| 08-11 | DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 | |
| 08-10 | DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | |||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- DMAC Stock
- Consensus DiaMedica Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
